Ann: CAN-003 INTERIM ANALYSIS PRESENTATION , page-3

The market action is translating it for you eagle....nothing new equals no interest from the market.......

ASX announcement 10 years ago (2002 Annual Report).......

""MANNAN ADJUVANT TECHNOLOGY
Immunological adjuvants can play a key role in the type, strength
and persistence of immune responses following immunisation with
specific antigens. Many adjuvants are able to stimulate the B cell
(antibody) arm of the immune system, but far fewer are able to
effectively stimulate effective T cell (cellular) immune responses.
Cancer Vac has shown that the attachment of antigens to mannan
(polymannose) enables the stimulation of cellular immune
responses (cytotoxic T lymphocytes (CTL’s)) to the antigen.
Cancer Vac has focused on the antigen mucin 1 (MUC1). Mucins
are present on normal cells but are expressed at significantly
higher levels in breast, ovarian & pancreatic cancer. Cancer
Vac technology combines mannan and MUC1 to create the
mannan-MAC1 stimulant.
Earlier studies, direct immunisation of subjects failed to induce
significant cellular immune responses. Subsequently, we have
assessed the ability of the mannan – MUC1 conjugate to effectively
prime isolated DCs, which are then re-injected into the patients.
Using this strategy we have seen a significant improvement, with
cellular immune responses to MUC1 produced in all patients that
have completed treatment.
Preliminary data generated from an ongoing clinical trial in cancer
patients, evaluating ex vivo priming of DCs with the vaccine, has
demonstrated that mannan – MUC1 primed DCs are well tolerated
following re-injection into patients and that all patients who have
completed treatment and follow-up evaluation have developed
strong antigen (MUC1)-specific T cell responses. This can be
demonstrated by showing the increasing number of MUC1-specific
T cells in the circulation of patients following treatment.""